Phaseline

Targets › GAS6

GAS6 (Growth arrest-specific protein 6): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology.

Ligand for tyrosine-protein kinase receptors AXL, TYRO3 and MER whose signaling is implicated in cell growth and survival, cell adhesion and cell migration. GAS6/AXL signaling plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone…. (UniProt, Q14393)

Open in Phaseline: the race on GAS6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of OklahomaBatiraxcept
Growth arrest-specific protein 6 inhibitor
GAS6Phase 1Urothelial Carcinoma–

Conditions

Urothelial Carcinoma (1)

Modalities

mixed (1)

Companies

University of Oklahoma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.